Investor Presentation Q1FY2027

HEIL/SE-28/2026-27 August 11, 2026 To, To, The Manager (Listing), The Manager (Listing), The BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, "Exchange Plaza", C-l, Block - G, Dalal Street, Bandra - Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Script Code No. : 543600 Symbol : HARSHA Dear Sir/Madam, Sub : Presentation on the Unudited Financial Results of the Company for the quarter ended June 30, 2026 Ref : Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to subject matter and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are enclosing herewith presentation on the Unudited Financial Results of the Company for the quarter ended June 30, 2026. The aforesaid presentation would also be available on the website of the Company viz; www.harshaengineers.com in accordance with Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. Kindly take the same on your records. Thanking you, Yours faithfully, FOR HARSHA ENGINEERS INTERNATIONAL LIMITED Kiran Mohanty Company Secretary and Chief Compliance Officer MEM NO. : F9907 Harsha Engineers International Limited CIN : L29307GJ2010PLC063233 Corporate & Registered Office: Sarkhej - Bavla Road, Changodar, Ahmedabad, Sanand - 382213, Gujarat, India. Tel.: +91-2717-618200 Fax: +91-2717-618259 E-mail: sec@harshaengineers.com URL: www.harshaengineers.com Harsha Engineers International Limited Earnings Presentation – Quarter ended June’26 Disclaimer/ Safe Harbor Cautionary statement regarding forward-looking statements ● This presentation may contain certain forward-looking statements relating to Harsha Engineers International Limited (“HEIL”, or “Company””) and its future business, development and economic performance. These statements include descriptions regarding the intent, belief or current expectations of the Company, its subsidiaries and associates and their respective directors and officers with respect to the results of operations and financial condition of the Company, subsidiary or associate, as the case may be. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to (1) competitive pressures; (2) legislative and regulatory developments; (3) global, macroeconomic and political trends; (4) fluctuations in currency exchange rates and general financial market conditions; (5) delay or inability in obtaining approvals from authorities; (6) technical developments; (7) litigation; (8) adverse publicity and news coverage, which could cause actual development and results to differ materially from the statements made in this presentation. Company assumes no obligation to update or alter forward-looking statements whether as a result of new information, future events or otherwise. Any forward-looking statements and projections made by third parties included in this presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. ● This presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this presentation. This presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this presentation is expressly excluded. ● This presentation does not constitute a prospectus, offering circular or offering memorandum or an offer, or a solicitation of any offer, to purchase or sell, any shares and should not be considered as a recommendation that any investor should subscribe for or purchase any of company’s securities in any jurisdiction. Neither this presentation nor any other 247 documentation or information (or any part thereof) delivered or supplied under or in relation to the shares shall be deemed to constitute an offer of or an invitation by or on behalf of 123 company. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any of 38 company’s securities. ● HEIL assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this document, the information contained herein is based on management information and estimates. The information contained herein is 6 subject to change without notice and past performance is not indicative of future results. HEIL may alter, modify or otherwise change in any manner the content of this presentation, 128 without obligation to notify any person of such revision or changes. ● No person is authorized to give any information or to make any representation not contained in and not consistent with this presentation and, if given or made, such information or representation must not be relied upon as having been authorized by or on behalf of HEIL. ● This presentation and its contents are confidential and should not be distributed, published or reproduced, in whole or in part, or disclosed by recipients directly or indirectly to any other person. 2 Privileged & Confidential, © 2022, All Rights Reserved. Index Quarter and Year End Highlights 219 Business Update Summary on use of IPO Proceeds Company Overview 3 Privileged & Confidential, © 2022, All Rights Reserved. QUARTER END HIGHLIGHTS Financial Highlights - QoQ ₹ in Lakhs 48 Revenue - Engineering CONSOLIDATED EBITDA - Engineering CONSOLIDATED PAT - Engineering CONSOLIDATED 153 EBITDA EBITDA % PAT PAT % Revenue outside 59.2%^ 56.9% 60.2% 20.2% 11.2% India (% 35000 ) 8,000 18.7% 16.6% 10.7% 8.4% 0 30000 7,000 171 25000 6,000 42,108 78 20000 38,207 34,883 5,000 7,707 4,269 15000 6,526 6,979 3,726 3,528 4,000 10000 219 5000 3,000 33 0 2,000 Q1FY26 Q4FY26 Q1FY27 40 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Revenue - Engineering INDIA EBITDA - Engineering INDIA PAT - Engineering INDIA 247 9,000 EBITDA EBITDA % PAT PAT % 1 32 83 44.4%^ 42.7% 44.7% 8,000 26.5% 22.4% 16.0% Revenue 7,000 24.9% 15.5% outside 26000 12.7% India (%)^ 6,000 21000 5,000 128 16000 29,204 30,996 4,000 7,752 25,647 6,950 4,663 195 11000 3,000 6,385 3,983 3,932 6000 2,000 1000 1,000 191 -4000 Q1FY26 Q4FY26 Q1FY27 0 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 EBITDA = Profit/ (Loss) Before Taxation+ Depreciation and Amortisation + Finance Cost ^ R5estatePdrivileged & Confidential, © 2022, All Rights Reserved. Business Update 153 • The consolidated revenue in Q1 FY 2027 has grown by 25.2% on YOY basis, reflecting continued strong Demand trends in India, as well as improving Demand for Industrials in Key markets of Europe and ROW. 171 • Our India Engineering business (HEIL + Advantek) has posted a 21% growth in Q1 FY 2027 on YOY basis. • Compression in EBITDA and PAT margins in Q1 FY 2027 in India Engineering Business is owing to Raw 219 material cost increase by around 6 to 8% during the quarter which will be passed through in subsequent quarters, a Forex loss of around Rs. 4 crores on account of settlement of cash flow hedge of previous quarters and higher cost of indirect materials like oil, packing material etc. by around Rs. 3 crores. • Our WOS Harsha Advantek has reported revenues of Rs. 30 crores in Q1 FY 2027 showing a 7% growth on a 38 QOQ basis. Advantek has reported a slightly lower EBITDA in Q1 FY 2027 resulting into a PAT loss of Rs. 4.3 crores, but on full year basis Advantek is expected to be PAT Positive. 128 • Sales of Bu [Showing first 8,000 characters — download PDF for full document]